Huons Enters Vaccine Market, Signs Distribution Deal with Sanofi for Five Vaccines
Establishment of Vaccine Business Division
Huons, a subsidiary of Huons Group, is entering the vaccine market in partnership with Sanofi Korea, the Korean branch of the global biopharmaceutical company Sanofi.
On March 25, Huons signed a contract at its headquarters in Pangyo, Seongnam, Gyeonggi Province, with Sanofi for domestic distribution and co-promotion (joint sales and marketing) of five types of injectable vaccines.
Huons signed a distribution contract for five types of vaccines with Sanofi on the 25th at the Huons Group headquarters in Pangyo, Seongnam. Soo-young Song, CEO of Huons (left), and Heekyung Park, Head of Vaccine Business Division at Sanofi Korea (right), are taking a commemorative photo. Photo by Huons
View original imageThrough this agreement, starting April 1, Huons will be responsible for the domestic distribution and promotion of a total of five vaccines: the influenza vaccines “Vaxigrip” (standard-dose) and “Efluelda” (high-dose); and, for adult immunization, the diphtheria/tetanus/pertussis vaccine “Adacel,” the hepatitis A vaccine “Avaxim160,” and the meningococcal vaccine “MenQuadfi.”
Sanofi is a global biopharmaceutical company that accelerates innovation through research and development (R&D) and artificial intelligence (AI), supplying medicines and vaccines that treat and protect millions of people worldwide. Huons possesses expertise in injectable sales and cold chain logistics in Korea. Both companies expect that their respective strengths will create synergy in targeting the domestic vaccine market.
Recently, Huons established a dedicated Vaccine Business Division to systematically promote its vaccine business. By leveraging its experienced sales professionals and existing customer network, the company plans to offer world-class vaccine accessibility to healthcare professionals and patients in Korea.
In particular, Huons aims to utilize its cold chain management technology and logistics infrastructure, developed through experience in distributing refrigerated injectables such as “Merit C Injection” and “Hudaxin Injection,” to reliably deliver temperature- and sensitivity-critical vaccines to medical institutions nationwide.
Soo-Young Song, CEO of Huons, stated, “Collaboration with Sanofi, a company recognized for its scientific credibility and quality in the global vaccine field, will be an important turning point for Huons to grow as a global public health partner. By combining Sanofi’s innovative solutions with Huons’ expertise in pharmaceutical sales, we will set new standards in the domestic vaccine market.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Huons plans to use its strategic partnerships with multinational pharmaceutical companies as a new growth engine for its vaccine business, expanding its pipeline and strengthening sustainable growth drivers.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.